|
 For more information please contact:
Richard Moyer
212.554.5466
richard@cameronassoc.com |
QuickLinks:
Press Releases »
Client Website »
Stock Quote »
Client Calendar » |
|
Cytori Therapeutics (NASDAQ: CYTX)
Cytori develops and globally commercializes regenerative medicine technologies, which provide real-time, point-of-care access to clinical grade regenerative cells. Our technology is incorporated into two product families. The Celution(R)-related products are sold throughout Europe and Asia primarily into the cosmetic and reconstructive surgery market and are under evaluation by the U.S. FDA. Our StemSource(R) products are sold globally for cell banking and research applications. We are also developing additional clinical uses of our technology for the treatment of multiple medical conditions, including cardiovascular disease, urinary tract disorders, and wound related conditions. To commercialize our technology, Cytori has partnered with global and regional leaders in healthcare such as Olympus Corporation, GE Healthcare, and Green Hospital Supply.
|
December 19, 2011
Cytori Completes IDE Filing for Chronic Myocardial Ischemia ATHENA Trial of the Celution(R) System
- download pdf (18 kb) »
|
September 23, 2011
Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement
- download pdf (12 kb) »
|
June 8, 2011
Cytori Reports Sustained Benefits at 18 Months in Cardiac Cell Therapy Heart Attack Trial
- download pdf (623 kb) »
|
May 31, 2011
NHS National Innovation Centre Identifies Celution(R) as Cost-Effective Innovative Technology for Partial Breast Reconstruction
- download pdf (21 kb) »
|
November 4, 2010:
Cytori Reports Third Quarter & Nine Month 2010 Results
- download word.doc (40 Kb) »
|
October 13, 2010:
Cytori Announces Exercise in Full of Overallotment Option and Closing of Public Offering of Common Stock
- download word.doc (40 Kb) »
|
October 8, 2010:
Cytori Therapeutics Prices Public Offering of Common Stock
- download word.doc (40 Kb) »
|
September 16, 2010:
Cytori Extends Distribution Agreement with GE Healthcare; Key Focus on Research Market
- download word.doc (40 Kb) »
|
August 12, 2010:
Cytori Issued Celution® System Patent for Orthopedic & Spinal Disc Diseases
- download word.doc (40 Kb) »
|
August 6, 2010:
Q2 2010 Shareholder Letter
- download word.doc (40 Kb) »
|
August 6, 2010:
Cytori Reports Second Quarter & First Half 2010 Results; Product Sales Up 64% and Gross Profit Up 141%
- download word.doc (40 Kb) »
|
July 27, 2010:
Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair
- download word.doc (40 Kb) »
|
June 17, 2010:
Breast Cancer Reconstruction Using Cell-Enriched Fat Grafts Shows Continued High Rates of Physician and Patient Satisfaction at 12 Months
- download word.doc (40 Kb) »
|
June 14, 2010:
Cytori Secures $20 Million Loan Facility Led by GE Capital, Healthcare Financial Services
- download word.doc (40 Kb) »
|
May 18, 2010:
Cytori Sells First U.S. StemSource(R) Cell Bank
- download word.doc (40 Kb) »
|
May 7, 2010:
Cytori Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial
- download word.doc (40 Kb) »
|
May 7, 2010:
Cytori Reports Stem & Regenerative Cells from Body Fat Produce Statistically Significant Improvement in Heart Function in Chronic Ischemia Trial
- download word.doc (40 Kb) »
|
May 6, 2010:
Cytori Reports First Quarter Results
- download word.doc (40 Kb) »
|
April 22, 2010:
PureGraft Enters the Market as an Innovative New System for Safe, Fast and Reliable Fat Grafting Procedures
- download word.doc (40 Kb) »
|
March 12, 2010:
Cytori Reports 2009 Financial Results
- download word.doc (40 Kb) »
|
January 27, 2010:
Cytori's StemSource(R) Cell Bank to Be Installed at Leading Cosmetic & Reconstructive Surgery Network in Japan
- download word.doc (40 Kb) »
|
January 26, 2010:
Cytori Issued U.S. Patent for Cell-Enriched Fat Grafting; New Patent Protects Key Cytori Market
- download word.doc (40 Kb) »
|
January 8, 2010:
FDA Grants 510(k) Marketing Clearance for Cytoris PureGraft System; First & Only Device on Market for Aesthetic Body Contouring using Autologous Fat Grafts
- download word.doc (40 Kb) »
|
September 14, 2009:
Cytori Reports Preclinical Results that Suggest Adipose-Derived Regenerative Cells may Reverse Periodontal Disease
- download word.doc (40 Kb) »
|
August 10, 2009:
Cytori Reports 2nd Quarter 2009 Financial Results
- download word.doc (40 Kb) »
|
July 17, 2009:
Cytori's Celution® 700 System to be Regulated as a Medical Device by U.S. FDA
- download word.doc (40 Kb) »
|
